[177Lu]-PSMA-617 is a novel treatment modality for prostate cancer, utilizing the tumor’s expression of PSMA as a target to allow for the administration of mixed beta–gamma radiation directly to the site of active metastases. The gene discussed is FOLH1; the disease is prostate carcinoma.